Gitelman Syndrome Clinical Trial
Official title:
Exploratory Study Into the Effect of Salt Supplementation in Gitelman Syndrome
The purpose of this study is to determine the effect of salt (NaCl) supplementation on serum potassium and clinical signs and symptoms in patients with Gitelman syndrome.
Single subject multiple randomized double-blinded multi-crossover placebo-controlled trials (N-of-1 trials) will be performed. Participants will enroll the study after giving written informed consent. The individual trials will consist of 3 treatment blocks which each contain a 4-week treatment period of salt supplementation (12 grams of NaCl) and a 4-week treatment period of placebo, in a randomized, blinded order. After each period of 4 weeks, outcomes measures will be measured. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06065852 -
National Registry of Rare Kidney Diseases
|
||
| Completed |
NCT02297048 -
Monocentric STUDY, Randomised Double Blinded (Healthy Subjects, or Transversal (Patients With Gitelman Syndrome)
|
Phase 4 | |
| Completed |
NCT00822107 -
A Translational Approach to Gitelman Syndrome
|
N/A | |
| Completed |
NCT01146197 -
Input of the Use of Indometacin in Gitelman Syndrome as Compared to Potassium Sparing Diuretics
|
Phase 1/Phase 2 |